Pharmacogenomic considerations for customizing warfarin therapy in the orthopedic patient

Orthopedics. 2010 Nov;33(11):828. doi: 10.3928/01477447-20100924-19.

Authors

Sonja Rhee¹, Kelly Walsh, Daniel Lewis, George Davis, Kelly M Smith

Affiliation

¹ University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.

PMID: 21053849
DOI: 10.3928/01477447-20100924-19

No abstract available

MeSH terms

Anticoagulants / pharmacokinetics
Anticoagulants / therapeutic use*
Aryl Hydrocarbon Hydroxylases / genetics
Cytochrome P-450 CYP2C9
Genetic Testing*
Genetic Variation*
Genotype
Humans
Mixed Function Oxygenases / genetics
Orthopedics / methods*
Patient Care Planning
Pharmacogenetics*
Venous Thromboembolism / genetics
Venous Thromboembolism / prevention & control
Vitamin K Epoxide Reductases
Warfarin / pharmacokinetics
Warfarin / therapeutic use*

Substances

Anticoagulants
Warfarin
Mixed Function Oxygenases
CYP2C9 protein, human
Cytochrome P-450 CYP2C9
Aryl Hydrocarbon Hydroxylases
Vitamin K Epoxide Reductases